Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) have been given a consensus recommendation of “Buy” by the eleven research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $54.63.

Several equities analysts recently weighed in on BHVN shares. Needham & Company LLC restated a “buy” rating and set a $56.00 price target (up previously from $48.00) on shares of Biohaven Pharmaceutical in a research report on Monday, March 4th. Cantor Fitzgerald increased their price target on shares of Biohaven Pharmaceutical to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Zacks Investment Research lowered shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. ValuEngine upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Oppenheimer set a $63.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, December 10th.

NYSE BHVN opened at $49.44 on Thursday. Biohaven Pharmaceutical has a 1 year low of $16.50 and a 1 year high of $50.65. The firm has a market capitalization of $2.22 billion, a PE ratio of -8.05 and a beta of 0.46.

In other Biohaven Pharmaceutical news, CEO Vlad Coric sold 100,000 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $50.09, for a total transaction of $5,009,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John Tilton sold 10,500 shares of the company’s stock in a transaction dated Thursday, January 10th. The shares were sold at an average price of $37.67, for a total transaction of $395,535.00. Following the sale, the insider now directly owns 10,500 shares in the company, valued at $395,535. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 304,180 shares of company stock worth $14,505,289. Insiders own 34.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in BHVN. Stifel Financial Corp lifted its holdings in shares of Biohaven Pharmaceutical by 555.2% in the fourth quarter. Stifel Financial Corp now owns 2,719,538 shares of the company’s stock worth $100,569,000 after buying an additional 2,304,438 shares in the last quarter. Brown Advisory Inc. bought a new position in shares of Biohaven Pharmaceutical in the fourth quarter worth approximately $16,766,000. TIAA CREF Investment Management LLC increased its position in shares of Biohaven Pharmaceutical by 670.0% in the third quarter. TIAA CREF Investment Management LLC now owns 463,254 shares of the company’s stock worth $17,395,000 after purchasing an additional 403,092 shares during the last quarter. Aisling Capital Management LP bought a new position in shares of Biohaven Pharmaceutical in the fourth quarter worth approximately $10,151,000. Finally, Samlyn Capital LLC increased its position in shares of Biohaven Pharmaceutical by 32.8% in the fourth quarter. Samlyn Capital LLC now owns 921,536 shares of the company’s stock worth $34,078,000 after purchasing an additional 227,432 shares during the last quarter. 88.91% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Featured Story: Day Trading

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.